Drug intelligence / Profile preview

dHER2 + AS15 ASCI + lapatinib

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules, Vaccines & Immunotherapeutics
Administration: Intramuscular, Oral

Overview

A combination therapy consisting of dHER2+AS15 cancer immunotherapeutic (ASCI) and lapatinib. The dHER2+AS15 ASCI contains a recombinant protein termed dHER2, which is a truncated version of the HER2 protein commonly overexpressed in breast cancer, combined with the immunological adjuvant AS15 Adjuvant System, a liposomal formulation containing three immunostimulatory components. Lapatinib is an oral dual tyrosine kinase inhibitor that targets both HER2 and EGFR. This combination approach aims to leverage both immune stimulation via the cancer vaccine and direct HER2/EGFR inhibition to treat HER2-positive metastatic breast cancer that is resistant to trastuzumab.

Other names: dual HER2 blockade with autologous dendritic cell vaccine targeting HER2 (dHER2 ASCI) plus lapatinib

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on dHER2 + AS15 ASCI + lapatinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dHER2 + AS15 ASCI + lapatinib.

Explore the full profile